Entity Central Index Key Lessee operating lease liability payments due after year three. Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Trading Symbol Trading Symbol Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Current Reporting Status Entity Current Reporting Status Entity Interactive Data Current Entity Interactive Data Current Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity Small Business Entity Small Business Entity Emerging Growth Company Entity Emerging Growth Company Entity Shell Company Entity Shell Company Title of 12(b) Security Security12b Title Security Exchange Name Security Exchange Name Entity File Number Entity File Number Entity Incorporation, State or Country Code Entity Incorporation State Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, Address Line Two Entity Address Address Line2 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Entity Common Stock, Shares Outstanding Entity Common Stock Shares Outstanding Document Quarterly Report Document Quarterly Report Document Transition Report Document Transition Report The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer. as well as trade accounts receivable, notes and loans receivable. Statement Of Financial Position [Abstract] Assets Assets [Abstract] Current assets: Assets Current [Abstract] Cash and cash equivalents Cash And Cash Equivalents At Carrying Value Accounts receivable Accounts Receivable Net Current Prepaid expenses and other current assets Prepaid Expenses And Other Receivables Total current assets Assets Current Property and equipment, net Property Plant And Equipment Net Operating lease right-of-use asset, net Operating Lease Right Of Use Asset Equity-method investment Equity Method Investments Non-current restricted cash Restricted Cash Noncurrent Total assets Assets Liabilities and stockholders’ equity Liabilities And Stockholders Equity [Abstract] Current liabilities: Liabilities Current [Abstract] Accounts payable Accounts Payable Current Accrued liabilities Accrued Liabilities Current Deferred revenue Deferred Revenue Current Total current liabilities Liabilities Current Deferred revenue, net of current portion Deferred Revenue Noncurrent Long-term debt, net of current portion Long Term Debt Noncurrent Operating lease liability, net of current portion Operating Lease Liability Noncurrent Other long-term liabilities Other Liabilities Noncurrent Total liabilities Liabilities Stockholders’ equity Stockholders Equity [Abstract] Common stock: $0.001 par value; 60,000 shares authorized; 26,349 issued and outstanding at September 30, 2021 and 26,192 issued and outstanding at December 31, 2020 Common Stock Value Additional paid-in capital Additional Paid In Capital Accumulated deficit Retained Earnings Accumulated Deficit Total stockholders’ equity Stockholders Equity Total liabilities and stockholders’ equity Liabilities And Stockholders Equity Common stock, par value Common Stock Par Or Stated Value Per Share Common stock, shares authorized Common Stock Shares Authorized Common stock, shares issued Common Stock Shares Issued Common stock, shares outstanding Common Stock Shares Outstanding Statement Of Income And Comprehensive Income [Abstract] Revenue Revenue From Contract With Customer Excluding Assessed Tax Operating expenses: Operating Expenses [Abstract] Research and development, net Research And Development Expense General and administrative General And Administrative Expense Total operating expenses Operating Expenses Loss from operations Operating Income Loss (Loss) gain from equity-method investment Income Loss From Equity Method Investments Gain from foreign currency Foreign Currency Transaction Gain Loss Before Tax Finance expense, net Other Nonoperating Income Expense Net loss Net Income Loss Net loss per share, basic and diluted Earnings Per Share Basic And Diluted Weighted-average shares outstanding, basic and diluted Weighted Average Number Of Share Outstanding Basic And Diluted Comprehensive loss: Comprehensive Income Net Of Tax [Abstract] Net loss Comprehensive loss Comprehensive Income Net Of Tax Stock issued during period shares under equity plan. Stock issued during period value under equity plan. Stock issued during period value option exercised. Stock issued during period shares option exercised. Statement Of Stockholders Equity [Abstract] Statement [Table] Statement [Table] Common Stock [Member] Statement Equity Components [Axis] Equity Component Equity Component [Domain] Common Stock [Member] Common Stock [Member] Additional Paid-In Capital [Member] Additional Paid In Capital [Member] Accumulated Deficit [Member] Retained Earnings [Member] Counterparty Name Counterparty Name [Axis] Counterparty Name Repurchase Agreement Counterparty Name [Domain] Ultragenyx. Ultragenyx [Member] Ultragenyx [Member] Statement [Line Items] Statement [Line Items] Balance Balance (in shares) Shares Outstanding Issuance of common stock related to acquired in-process research and development Stock Issued During Period Value Acquisitions Issuance of common stock related to acquired in-process research and development (in shares) Stock Issued During Period Shares Acquisitions Issuance of common stock, net of issuance costs Stock Issued During Period Value New Issues Issuance of common stock, net of issuance costs (in shares) Stock Issued During Period Shares New Issues Issuance of common stock to Ultragenyx on option exercise Stock Issued During Period Value Option Exercised Issuance of common stock to Ultragenyx on option exercise (in shares) Stock Issued During Period Shares Option Exercised Share-based compensation expense Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value Issuance of common stock upon exercise of stock options Stock Issued During Period Value Stock Options Exercised Issuance of common stock upon exercise of stock options (in shares) Stock Issued During Period Shares Stock Options Exercised Issuance of common stock under equity plans Stock Issued During Period Value Under Equity Plan Issuance of common stock under equity plans (in shares) Stock Issued During Period Shares Under Equity Plan Balance Balance (in shares) Proceeds from issuance of common stock on option exercise. Statement Of Cash Flows [Abstract] OPERATING ACTIVITIES: Net Cash Provided By Used In Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Depreciation and amortization Depreciation And Amortization Share-based compensation expense Share Based Compensation Acquired in-process research and development expense Research And Development In Process (Gain) loss from equity-method investment Foreign currency transaction gain Foreign Currency Transaction Gain Loss Realized Other non-cash expenses Other Noncash Income Expense Changes in operating assets and liabilities Increase Decrease In Operating Capital [Abstract] Accounts receivable Increase Decrease In Accounts Receivable Prepaid expense and other assets Increase Decrease In Prepaid Deferred Expense And Other Assets Accounts payable Increase Decrease In Accounts Payable Accrued liabilities Increase Decrease In Accrued Liabilities Deferred revenue Increase Decrease In Contract With Customer Liability Net cash used in operating activities Net Cash Provided By Used In Operating Activities INVESTING ACTIVITIES: Net Cash Provided By Used In Investing Activities [Abstract] Acquisition of property and equipment Payments To Acquire Property Plant And Equipment Net cash used in investing activities Net Cash Provided By Used In Investing Activities FINANCING ACTIVITIES: Net Cash Provided By Used In Financing Activities [Abstract] Proceeds from debt Proceeds From Issuance Of Debt Proceeds from issuance of common stock, net of issuance costs Proceeds From Issuance Of Common Stock Proceeds from the issuance of common stock to Ultragenyx on option exercise Proceeds From Issuance Of Common Stock On Option Exercise Proceeds from exercise of stock options Proceeds From Stock Options Exercised Proceeds from the issuance of common stock under equity plans Proceeds From Stock Plans Net cash provided by financing activities Net Cash Provided By Used In Financing Activities NET (DECREASE) INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Cash, cash equivalents and restricted cash at beginning of the period Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Cash, cash equivalents and restricted cash at end of the period Acquisition of research and development in process through issuance of common stock. Supplemental disclosure of cash flow information Supplemental Cash Flow Information [Abstract] Cash paid for interest Interest Paid Net Non-cash investing activities Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract] Right-of-use asset obtained in exchange for lease liabilities Right Of Use Asset Obtained In Exchange For Operating Lease Liability Acquisition of in-process research and development through issuance of common stock Acquisition Of Research And Development In Process Through Issuance Of Common Stock Purchase of property and equipment in accounts payable Capital Expenditures Incurred But Not Yet Paid Accounting Policies [Abstract] Description of Business, Basis of Presentation and Summary of Significant Accounting Policies Organization Consolidation Basis Of Presentation Business Description And Accounting Policies [Text Block] Revenue From Contract With Customer [Abstract] Revenue Revenue From Contract With Customer [Text Block] Fair Value Disclosures [Abstract] Fair Value Measurements Fair Value Disclosures [Text Block] Balance Sheet Related Disclosures [Abstract] Balance Sheet Details Supplemental Balance Sheet Disclosures [Text Block] Debt Disclosure [Abstract] Debt Debt Disclosure [Text Block] Stockholders Equity Note [Abstract] Stockholders' Equity Stockholders Equity Note Disclosure [Text Block] Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] Share-Based Compensation Disclosure Of Compensation Related Costs Share Based Payments [Text Block] Income Tax Disclosure [Abstract] Income Taxes Income Tax Disclosure [Text Block] Commitments And Contingencies Disclosure [Abstract] Commitments and Contingencies Commitments And Contingencies Disclosure [Text Block] Related Party Transactions [Abstract] Related Party Transactions Related Party Transactions Disclosure [Text Block] Subsequent Events [Abstract] Subsequent Events Subsequent Events [Text Block] Basis of Presentation Basis Of Accounting Policy Policy [Text Block] Joint ventures, equity method investments and variable interest entities. Joint Ventures, Equity Method Investments and Variable Interest Entities Joint Ventures Equity Method Investments And Variable Interest Entities Policy [Text Block] Liquidity. Liquidity Liquidity Policy Policy [Text Block] Segment Information Segment Reporting Policy Policy [Text Block] Revenue Recognition Revenue Recognition Policy [Text Block] Leases Lessee Leases Policy [Text Block] Research and Development, Net Research And Development Expense Policy Pre-launch inventory policy. Pre-Launch Inventory Pre Launch Inventory Policy Policy [Text Block] Statement of Cash Flows Inventory Cash Flow Policy Net Loss per Share Earnings Per Share Policy [Text Block] Schedule of Cash and Cash Equivalents and Restricted Cash Schedule Of Cash And Cash Equivalents Table [Text Block] Summary of Changes in Balances of Contract Assets and Contract Liability Contract With Customer Asset And Liability Table [Text Block] Schedule of Revenue Disaggregation Of Revenue Table [Text Block] Summary of Components of Property and Equipment, Net Property Plant And Equipment [Text Block] Schedule of Accrued Liabilities Schedule Of Accrued Liabilities Table [Text Block] Schedule of Maturities of Long-term Debt Schedule Of Maturities Of Long Term Debt Table [Text Block] Schedule of Share-based Compensation Expenses Schedule Of Compensation Cost For Share Based Payment Arrangements Allocation Of Share Based Compensation Costs By Plan Table [Text Block] Remaining Payments of Operating Lease Liability Lessee Operating Lease Liability Maturity Table [Text Block] Summary of significant accounting policy. Schedule of summary of significant accounting policies. Schedule Of Summary Of Significant Accounting Policies [Table] Schedule Of Summary Of Significant Accounting Policies [Table] Investment, Name Schedule Of Equity Method Investment Equity Method Investee Name [Axis] Investment, Name Equity Method Investee Name [Domain] Axcelead, Inc. Axcelead, Inc [Member] Axcelead Inc [Member] Equity Method Investment, Nonconsolidated Investee Equity Method Investment Nonconsolidated Investee [Axis] Equity Method Investment, Nonconsolidated Investee Equity Method Investment Nonconsolidated Investee [Domain] Vallon Pharmaceuticals, Inc. Vallon Pharmaceuticals, Inc. [Member] Vallon Pharmaceuticals Inc [Member] Statistical Measurement Range [Axis] Statistical Measurement Range [Member] Maximum [Member] Maximum [Member] Minimum [Member] Minimum [Member] Geographical Statement Geographical [Axis] Geographical Segment Geographical [Domain] Singapore Economic Development Board [Member] S G Sale of Stock Subsidiary Sale Of Stock [Axis] Sale of Stock Sale Of Stock Name Of Transaction [Domain] Underwritten public offering. Underwritten Public Offering [Member] Underwritten Public Offering [Member] Summary Of Significant Accounting Policy [Line Items] Summary Of Significant Accounting Policy [Line Items] Equity method ownership percentage Equity Method Investment Ownership Percentage Percentage of owned shares Investment Owned Percent Of Net Assets Percentage of equity interest in joint venture. Upfront fee/consideration. Investment in joint venture Equity Method Investment Aggregate Cost Upfront fee/consideration Upfront Fee And Consideration Cash consideration paid for equity interest in joint venture Payments To Acquire Interest In Joint Venture Percentage of equity interest in joint venture Percentage Of Equity Interest In Joint Venture Accumulated deficit Nonrefundable upfront payment received. Term loan Debt Instrument Face Amount Nonrefundable upfront payment received Nonrefundable Upfront Payment Received Number of operating segment for research and development Number Of Operating Segments Non-current restricted cash Total cash, cash equivalents and restricted cash shown in the statement of cash flows Dividends declared or paid Dividends Contract with customer asset additions for revenue recognized. Contract with customer asset deductions for cash collections. Contract With Customer Liability Additions For Advanced Billings Contract Assets, Balance Contract With Customer Asset Net Contract Assets, Additions for revenue recognized from billings Contract With Customer Asset Additions For Revenue Recognized Contract Assets, Deductions for cash collections Contract With Customer Asset Deductions For Cash Collections Contract Assets, Balance Contract Liabilities, Balance Contract With Customer Liability Contract Liabilities, Additions for advanced billings Contract With Customer Liability Additions For Advanced Billings Deductions for promised services provided in current period Contract With Customer Liability Revenue Recognized Contract Liabilities, Balance Disaggregation Of Revenue [Table] Disaggregation Of Revenue [Table] Vinbiotech. Vinbiotech [Member] Vinbiotech [Member] Janssen. Janssen [Member] Janssen [Member] CureVac AG. CureVac [Member] Cure Vac A G [Member] Other. Other [Member] Other [Member] Disaggregation Of Revenue [Line Items] Disaggregation Of Revenue [Line Items] Total revenue Upfront payment received. Revenue. Revenue. Revenue [Table] Revenue [Table] Collaborative Arrangement and Arrangement Other than Collaborative Type Of Arrangement [Axis] Collaborative Arrangement and Arrangement Other than Collaborative Arrangements And Nonarrangement Transactions [Member] Vinbiotech agreement. Vinbiotech Agreement [Member] Vinbiotech Agreement [Member] Accounting Standards Update Adjustments For New Accounting Pronouncements [Axis] Accounting Standards Update Type Of Adoption [Member] ASC 606 [Member] Accounting Standards Update201409 [Member] Research collaboration and license agreement. Research Collaboration And Exclusive License Agreement [Member] Research Collaboration And License Agreement [Member] Research Collaboration and Exclusive License Agreement. Research Collaboration And Exclusive License Agreement [Member] Research Collaboration And Exclusive License Agreement [Member] mRNA technology. mRNA Technology [Member] M R N A Technology [Member] Product and Service Product Or Service [Axis] Product and Service Products And Services [Domain] Rare disease targets. Rare Disease Targets [Member] Rare Disease Targets [Member] Non-rare disease targets. Non-Rare Disease Targets [Member] Non Rare Disease Targets [Member] Collaboration Partner Cure Vac entered into Co-Development Agreement. Collaboration Partner Cure Vac Entered Into Co Development Agreement [Member] Collaboration Partner Cure Vac Entered Into Co Development Agreement [Member] Other collaboration agreements. Other Collaboration Agreements [Member] Other Collaboration Agreements [Member] Related Party Related Party Transactions By Related Party [Axis] Related Party Related Party [Domain] Takeda Pharmaceutical Company Limited and Providence Therapeutics Incorporation. Takeda Pharmaceutical Company Limited [Member] Takeda Pharmaceutical Company Limited And Providence Therapeutics Incorporation [Member] Israeli Ministry of Health ("MOH") [Member] I L Revenue [Line Items] Revenue [Line Items] Upfront payment received Upfront Payment Received Number of performance obligations. Number of performance obligations Number Of Performance Obligations Deferred revenue Revenue recognition potential milestone revenue recognized. Revenue recognition potential milestone revenue recognized Revenue Recognition Potential Milestone Revenue Recognized Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Table] Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Table] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Start Date [Axis] Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items] Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items] Remaining research period Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 Remaining performance obligation Revenue Remaining Performance Obligation Option exercise revenue range per target. Option exercise fee revenue received. Option exercise revenue range per target Option Exercise Revenue Range Per Target Option exercise fee received Option Exercise Fee Revenue Received Royalty payment term description. Royalty payment term description Royalty Payment Term Description Number of reserve targets. Option to purchase of additional shares of common stock. Option to purchase of additional shares of common stock price per share. Number of targets Number Of Reserve Targets Purchase of common stock, shares Purchase of additional shares of common stock Option To Purchase Of Additional Shares Of Common Stock Purchase of additional shares of common stock price per share Option To Purchase Of Additional Shares Of Common Stock Price Per Share Collaboration agreement consideration received. Collaboration agreement transaction price. Lack of marketability discount restricted period. Consideration received Collaboration Agreement Consideration Received Consideration received for common stock purchase Sale Of Stock Consideration Received Per Transaction Transaction price Collaboration Agreement Transaction Price Lack of marketability discount restricted period Lack Of Marketability Discount Restricted Period Revenue, practical expedient description Revenue Practical Expedient Remaining Performance Obligation Description Revenue recognition reserve target exclusivity period. Revenue recognition, reserve target exclusivity period Revenue Recognition Reserve Target Exclusivity Period Development and option agreement date. Development and option agreement date Development And Option Agreement Date Expiration of initial term. Option to extend initial term on an annual basis. Expiration of initial term Expiration Of Intial Term Option to extend initial term on an annual basis Option To Extend Initial Term On An Annual Basis Potential target license term. Potential target license term Potential Target License Term Adjustments to transaction price. Adjustments to transaction price Adjustments To Transaction Price Upfront fee received. Collaboration agreement contractual term. Upfront fee received Upfront Fee Received Contractual term Collaboration Agreement Contractual Term Non-refundable payment received. Number of reserved vaccine doses. Non-refundable payment received Non Refundable Payment Received Number of reserved vaccine doses Number Of Reserved Vaccine Doses Property Plant And Equipment [Abstract] Schedule Of Property Plant And Equipment [Table] Schedule Of Property Plant And Equipment [Table] Long-Lived Tangible Asset Property Plant And Equipment By Type [Axis] Long-Lived Tangible Asset Property Plant And Equipment Type [Domain] Research equipment [Member] Equipment [Member] Computer and software [Member] Computer Equipment [Member] Office equipment and furniture [Member] Furniture And Fixtures [Member] Leasehold improvements [Member] Leasehold Improvements [Member] Construction in progress [Member] Construction In Progress [Member] Property Plant And Equipment [Line Items] Property Plant And Equipment [Line Items] Property and equipment, gross Property Plant And Equipment Gross Less accumulated depreciation and amortization Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Property and equipment, net Accrued cystic fibrosis foundation liability. Accrued singapore economic development board liability. Clinical accruals current. Other accrued research and development expenses. Accrued Liabilities Current [Abstract] Accrued compensation Employee Related Liabilities Current Cystic Fibrosis Foundation Liability (Note 9) Accrued Cystic Fibrosis Foundation Liability Singapore Economic Development Board liability Accrued Singapore Economic Development Board Liability Current portion of operating lease liability Operating Lease Liability Current Operating Lease Liability Current Statement Of Financial Position Extensible List Operating Lease Liability Current Statement Of Financial Position Extensible List Current portion of long-term debt Long Term Debt Current Clinical accruals Clinical Accruals Current Other accrued research and development expenses Other Accrued Research And Development Expenses Total Debt Instrument [Table] Debt Instrument [Table] Loan and security agreement. Loan and Security Agreement [Member] Loan And Security Agreement [Member] Western Alliance Bank. Western Alliance Bank [Member] Western Alliance Bank [Member] Long-term Debt, Type Longterm Debt Type [Axis] Long-term Debt, Type Longterm Debt Type [Domain] Long-term Debt [Member] Long Term Debt [Member] Subsequent Event Type Subsequent Event Type [Axis] Subsequent Event Type Subsequent Event Type [Domain] Subsequent Events [Member] Subsequent Event [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Term loan draw down Borrowings Under Guaranteed Investment Agreements Royalty payment percentage. Loan accrues interest rate per annum, percentage Debt Instrument Interest Rate Effective Percentage Royalty payment percentage of proceeds from net sales Royalty Payment Percentage Maximum sales required for loans forgivable . Maximum LUNAR-COVID 19 sales required for Loans forgivable Maximum Sales Required For Loans Forgivable Long-term debt Long Term Debt Interest expense related to long-term debt Interest Expense Long Term Debt Proceeds from long-term debt agreement Proceeds From Issuance Of Long Term Debt Percentage required to be maintained in consolidated unrestricted cash. Debt instrument, collateral Debt Instrument Collateral Percentage required to be maintain in consolidated, unrestricted cash Percentage Required To Be Maintained In Consolidated Unrestricted Cash Debt instrument, collateral amount Debt Instrument Collateral Amount Debt instrument interest only payment extended maturity date. Debt instrument interest only payment extended period. Loan maturity date Debt Instrument Maturity Date Interest of the prime rate plus Debt Instrument Basis Spread On Variable Rate1 Loan interest-only payment extended maturity date Debt Instrument Interest Only Payment Extended Maturity Date Extension to interest only period Debt Instrument Interest Only Payment Extended Period Loan first principal payment extended maturity date Debt Instrument Date Of First Required Payment1 Warrant fee payable. Loan origination fee paid Unamortized Loan Commitment And Origination Fees And Unamortized Discounts Or Premiums Warrant fee payable Warrant Fee Payable Prepayment fee percentage. Prepayment fee percentage Prepayment Fee Percentage 2021 Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year 2022 Long Term Debt Maturities Repayments Of Principal In Next Twelve Months 2023 Long Term Debt Maturities Repayments Of Principal In Year Two Total Schedule Of Stock By Class [Table] Schedule Of Stock By Class [Table] Alexion Pharmaceuticals, Inc. Alexion [Member] Alexion Pharmaceuticals Inc [Member] Class Of Stock [Line Items] Class Of Stock [Line Items] Issuance of common stock Common stock issued, value Stock Issued During Period Value Issued For Services Non-cash charge recorded in acquired in-process research and development expense Antidilutive securities excluded from computation of earnings per share Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Plan Name Plan Name [Axis] Plan Name Plan Name [Domain] Two thousand nineteen omnibus incentive plan. 2019 Omnibus Equity Incentive Plan [Member] Two Thousand Nineteen Omnibus Incentive Plan [Member] Award Type Award Type [Axis] Award Type Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain] Stock Option [Member] Employee Stock Option [Member] 2021 Inducement equity incentive plan. 2021 Inducement Equity Incentive Plan [Member] Twenty Twenty One Inducement Equity Incentive Plan [Member] Two Thousand Twenty Employee Stock Purchase Plan. 2020 Employee Stock Purchase Plan [Member] Two Thousand Twenty Employee Stock Purchase Plan [Member] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Share-based compensation number of shares authorized Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized Common stock reserved for future issuance Common Stock Capital Shares Reserved For Future Issuance Number of shares available Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Common stock purchased Share Based Compensation Arrangement By Share Based Payment Award Shares Purchased For Award Share-based compensation arrangement by share-based payment award, maximum discounted purchase price. Share based compensation arrangement by share based payment award maximum discounted amount. Maximum discounted purchase price Share Based Compensation Arrangement By Share Based Payment Award Maximum Discounted Purchase Price Share-based compensation expenses Allocated Share Based Compensation Expense Maximum discounted amount per year Share Based Compensation Arrangement By Share Based Payment Award Maximum Discounted Amount Income Statement Location Income Statement Location [Axis] Income Statement Location Income Statement Location [Domain] Research and Development [Member] Research And Development Expense [Member] General and Administrative [Member] General And Administrative Expense [Member] Share-based compensation expenses Income tax expense Income Tax Expense Benefit Contra research and development expense. Contra expense remaining amount included in accrued expenses. Commitment and contingencies. Commitment and contingencies. Commitment And Contingencies [Table] Commitment And Contingencies [Table] COVID-19 vaccine development. COVID-19 Vaccine Development C O V I D Nineteen Vaccine Development [Member] Grant one. Grant 1 Grant One [Member] Grant two. Grant 2 Grant Two [Member] LUNAR-CF. LUNAR-CF [Member] L U N A R C F [Member] Underlying agreement. Underlying Agreement [Member] Underlying Agreement [Member] Cystic Fibrosis Foundation Therapeutics, Inc. Cystic Fibrosis Foundation [Member] Cystic Fibrosis Foundation Therapeutics Inc [Member] Scenario Statement Scenario [Axis] Scenario Scenario Unspecified [Domain] Disbursement period one. Disbursement Due January 2020 [Member] Disbursement Period One [Member] Disbursement period two. Disbursement Due April 2020 [Member] Disbursement Period Two [Member] Disbursement period three. Disbursement Due July 2020 [Member] Disbursement Period Three [Member] Disbursement period four. Disbursement Due October 2020 [Member] Disbursement Period Four [Member] Lease Contractual Term Lease Contractual Term [Axis] Lease Contractual Term Lease Contractual Term [Domain] October 2017 lease amendment. October 2017 Lease Amendment [Member] October Two Thousand And Seventeen Lease Amendment [Member] February two thousand and twenty lease agreement. February 2020 Lease Agreement [Member] February Two Thousand And Twenty Lease Agreement [Member] February two thousand and twenty one lease agreement. February 2021 Lease Agreement [Member] February Two Thousand And Twenty One Lease Agreement [Member] September two thousand and twenty one lease agreement. September 2021 Lease Agreement [Member] September Two Thousand And Twenty One Lease Agreement [Member] Commitment And Contingencies [Line Items] Commitment And Contingencies [Line Items] Grant awarded Grants Receivable Contra research and development expense recognized Contra Research And Development Expense Contra expense remaining amount included in accrued expenses Contra Expense Remaining Amount Included In Accrued Expenses Grant receivable number of installments. Payment received first installment. Grant, number of installments Grant Receivable Number Of Installments Received first installment Payment Received First Installment Payments for matching funds for remaining budgeted costs. Disbursed amount upon execution of amendment. Disbursement amount payable upon achievement of project goal. Final payment of disbursement amount. Disbursement payment upon achievement of required manufacturing practices and IND application. Contra expense included in research and development expense. Payments for advance Payments For Advance To Affiliate Payments for matching funds for remaining budgeted costs Payments For Matching Funds For Remaining Budgeted Costs Disbursed amount upon execution of amendment Disbursed Amount Upon Execution Of Amendment Disbursement amount payable upon achievement of project goal Disbursement Amount Payable Upon Achievement Of Project Goal Final payment of disbursement amount Final Payment Of Disbursement Amount Disbursement payment upon achievement of required manufacturing practices and IND application Disbursement Payment Upon Achievement Of Required Manufacturing Practices And I N D Application Contra expense included in research and development expense Contra Expense Included In Research And Development Expense Operating lease extended additional term Lessee Operating Lease Renewal Term Lessee, operating lease, term of contract Lessee Operating Lease Term Of Contract Tenant improvement allowance Payments For Proceeds From Tenant Allowance Lessee, operating leases, option to extend Lessee Operating Lease Option To Extend Security deposit Security Deposit Monthly base rent. Monthly base rent Monthly Base Rent Leases [Abstract] 2021 Lessee Operating Lease Liability Payments Remainder Of Fiscal Year 2022 Lessee Operating Lease Liability Payments Due Next Twelve Months 2023 Lessee Operating Lease Liability Payments Due Year Two 2024 Lessee Operating Lease Liability Payments Due Year Three Thereafter Lessee Operating Lease Liability Payments Due After Year Three Total remaining lease payments Lessee Operating Lease Liability Payments Due Less: imputed interest Lessee Operating Lease Liability Undiscounted Excess Amount Total operating lease liabilities Operating Lease Liability Weighted-average remaining lease term Operating Lease Weighted Average Remaining Lease Term1 Weighted-average discount rate Operating Lease Weighted Average Discount Rate Percent Operating lease costs Operating Lease Cost Common stock shares restricted from selling period subsequent to issuance date. Schedule Of Related Party Transactions By Related Party [Table] Schedule Of Related Party Transactions By Related Party [Table] Collaboration partner Ultragenyx. Collaboration Partner - Ultragenyx [Member] Collaboration Partner Ultragenyx [Member] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Ownership interest of common stock Sale Of Stock Percentage Of Ownership After Transaction Common stock shares restricted from selling period subsequent to issuance date Common Stock Shares Restricted From Selling Period Subsequent To Issuance Date ADAIR Technology. ADAIR Technology [Member] A D A I R Technology [Member] Number of shares owned Investment Owned Balance Shares Share price Share Price Subsequent Event [Table] Subsequent Event [Table] Subsequent Event [Line Items] Subsequent Event [Line Items]